• by Paul Armentano, NORML Deputy Director September 2, 2015

    NORML is pleased to present the latest expanded/updated edition of the publication Emerging Clinical Applications for Cannabis & Cannabinoids — a comprehensive review of the latest peer-reviewed science specific to the safety and therapeutic efficacy of whole-plant cannabis and/or its components.

    The 2015 updated edition includes two additional disease profiles (Parkinson’s disease and PTS) and includes summaries of an additional 50+ relevant clinical and/or preclinical trials specific to cannabinoids’ therapeutic utility. Several existing sections, such as Chronic Pain, Diabetes, and Epilepsy, have been significantly expanded since the last edition (January 2013). Also updated is the Introduction to the Endocannabinoid System (authored by Dustin Sulak, DO) and Why I Recommend Medical Cannabis (authored by Estelle Goldstein, MD).

    With summaries and citations of well over 250 recent peer-reviewed studies, this updated publication is one of the most thorough and up-to-date source-books available specific to documenting the established therapeutic qualities of cannabis. The updated publication is available online here.

    Individual sections of this publication may be accessed at the links below:

    Author’s Introduction
    Introduction to the Endocannabinoid System
    Why I Recommend Medical Cannabis
    Alzheimer’s Disease
    Amyotrophic Lateral Sclerosis
    Chronic Pain
    Diabetes Mellitus
    Gastrointestinal Disorders
    Hepatitis C
    Human Immunodeficiency Virus
    Huntington’s Disease
    Methicillin-resistant Staphyloccus aureus (MRSA)
    Multiple Sclerosis
    Parkinson’s Disease
    Post-Traumatic Stress
    Rheumatoid Arthritis
    Sleep Apnea
    Tourette’s Syndrome

  • by Paul Armentano, NORML Deputy Director September 1, 2015

    Strains of cannabis sativa and cannabis indica possess relatively few significant genetic differences and are often mislabeled by breeders, according to an evaluation of marijuana taxonomy published online last week in the journal PLOS ONE.

    Investigators from the University of Manitoba, the University of British Columbia, and Dalhousie University in Nova Scotia evaluated the genetic structure of a diverse range of commonly cultivated marijuana and industrial hemp samples.

    Researchers reported, “We find a moderate correlation between the genetic structure of marijuana strains and their reported C. sativa and C. indica ancestry and show that marijuana strain names often do not reflect a meaningful genetic identity.” They added, “This observation suggests that C. sativa and C. indica may represent distinguishable pools of genetic diversity, but that breeding has resulted in considerable admixture between the two. … Our results suggest that the reported ancestry of some of the most common marijuana strains only partially captures their true ancestry.”

    By contrast, authors determined, “[M]arijuana and hemp are significantly differentiated at a genome-wide level, demonstrating that the distinction between these populations is not limited to genes underlying THC production. … [This] difference between marijuana and hemp plants has considerable legal implications in many countries.”

    In the United States, federal law makes no legal distinction between hemp and cannabis.

    Authors concluded: “Achieving a practical, accurate and reliable classification system for cannabis, including a variety registration system for marijuana-type plants, will require significant scientific investment and a legal framework that accepts both licit and illicit forms of this plant. Such a system is essential in order to realize the enormous potential of Cannabis as a multi-use crop (hemp) and as a medicinal plant (marijuana).”

    Full text of the study, “The genetic structure of marijuana and hemp,” appears online here.

  • by Paul Armentano, NORML Deputy Director August 26, 2015

    Latest JAMA Studies Largely Fail To Support Past Claims About Marijuana And Brain HealthTwo new studies published online today in JAMA (Journal of the American Medical Association) Psychiatry provide little support for previous claims that cannabis exposure is significantly harmful to the developing brain.

    The first study, which assessed the effects of cannabis exposure on brain volume in exposed and unexposed sibling pairs, reported that any identifiable differences “were attributable to common predispositional factors, genetic or environmental in origin.” By contrast, authors found “no evidence for the causal influence of cannabis exposure” on brain morphology.

    The trial is “the largest study to date examining the association between cannabis exposure (ever versus never used) and brain volumes.”

    The study is one of two recent clinical trials to be published in recent months rebutting the claims of a widely publicized 2014 paper which alleged that even casual marijuana exposure may be linked to brain abnormalities, particularly in the region of the brain known as the amygdala. In January, researchers writing in The Journal of Neuroscience reported “no statistically significant differences … between daily [marijuana] users and nonusers on [brain] volume or shape in the regions of interest” after researchers controlled for participants’ use of alcohol. Similarly, today’s JAMA study “casts considerable doubt on hypotheses that cannabis use … causes reductions in amygdala volumes.”

    A second study appearing today in the journal assessed whether cannabis use during adolescence is associated with brain changes that may be linked to an increased risk of schizophrenia. While researchers reported finding an association among male subjects who possessed a high genetic predisposition toward schizophrenia, authors reported that no such association existed among male subjects who were at low risk for the disease, or among females in either the high risk or low risk categories. The finding is consistent with the theory that early onset cannabis use may potentially exacerbate symptoms in a minority of subjects predisposed to the disease, but it contradicts claims that marijuana exposure is a likely cause of schizophrenia, particularly among those who are not already vulnerable to the disease.

    Abstracts of both new studies appear online in JAMA Psychiatry here and here.

  • by Paul Armentano, NORML Deputy Director August 18, 2015

    Inhaling cannabis is associated with the remission of refractory idiopathic angioedema, according to a clinical report published in the journal Case Reports in Immunology. Angioedema is a condition characterized by rapid swelling under the skin in regions around the face and throat, which may result in airway obstruction or suffocation.

    Investigators from the Soroka University Medical Center in Israel reported on the progress of a 27-year-old male patient with life-threatening, recurrent angioedema of unknown origin. Doctors placed the patient on a regiment of 20 grams of inhaled cannabis monthly after he failed to respond favorably to prescribed steroids and antihistamines.

    Authors reported: “The use of inhaled cannabis resulted in a complete response, and he has been free of symptoms for 2 years. An attempt to withhold the inhaled cannabis led to a recurrent attack within a week, and resuming cannabis maintained the remission, suggesting a cause and effect relationship.”

    They concluded: “This is the first report in which a cannabis product for the treatment of refractory idiopathic angioedema was associated with an excellent clinical response. … More research into the exact mechanism of action of cannabis products in cases of idiopathic angioedema and on the modulation of the immune response in general is indicated.”

    The Israeli government has authorized the limited production and distribution of marijuana as a medical treatment since 2011, and preparations of the plant are expected to be available in pharmacies imminently.

    Full text of the report, “Life threatening idiopathic recurrent angioedema responding to cannabis,” appears online here.

  • by Paul Armentano, NORML Deputy Director August 12, 2015

    Study: Cannabis Users Less Likely To Be Obese, Possess Lower Diabetes RiskA history of cannabis use is associated with a lower likelihood of obesity and diabetes, according to population-based data published in the journal Obesity.

    Investigators from the Conference of Quebec University Health Centers assessed cannabis use patterns and body mass index (BMI) in a cohort of 786 Inuit (Arctic aboriginal) adults ages 18 to 74. Researchers reported that subjects who consumed cannabis in the past year were more likely to possess a lower BMI, lower fasting insulin, and lower HOMA-IR (insulin resistance) as compared to those who did not use the substance.

    Specifically, researchers reported that cannabis users possessed an average BMI of 26.8 compared to an index of 28.6 for non-users, after controlling for age, gender and other factors. Those subjects who reported using cannabis but never having used tobacco, or who were former users of tobacco, possessed on average the lowest BMI.

    Authors concluded: “In this large cross-sectional adult survey with high prevalence of both substance use and obesity, cannabis use in the past year was associated with lower BMI, lower percentage fat mass, lower fasting insulin, and HOMA-IR. … The inverse association observed in our work supports evidence from a larger proportion of previous cross-sectional and follow-up investigations. … As a result, cannabinoids from cannabis may be viewed as an interesting avenue for research on obesity and associated conditions.”

    Observational trial data published in 2013 in the American Journal of Medicine reported that subjects who consumed cannabis possessed favorable indices related to diabetic control compared to those without a history of recent marijuana use. Separate observational trial data published in 2012 in the British Medical Journal reported that marijuana users had a lower prevalence of type 2 diabetes and possessed a lower risk of contracting the disease than did those with no history of cannabis consumption, even after researchers adjusted for social variables such as subjects’ ethnicity, family history, and levels of physical activity.

    Cross-sectional data published in 2011 in the American Journal of Epidemiology similarly reported that the prevalence of obesity in the general population is sharply lower among marijuana consumers than it is among nonusers.

Page 2 of 7212345...102030...Last »